Get Started

S2/E112. What's Coming in Obesity Medicine? The Med Pipeline with Dr. Sean Wharton

What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.


Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:


  • Semaglutide (Wegovy/Ozempic)
  • Tirzepatide (Mounjaro/Zepbound)
  • Retatrutide (GLP1, GIP, glucagon triple analogue)
  • Cagrisema (amylin/GLP1 dual analogue)
  • Bimagrumab (human monoclonal antibody)
  • Cannabinoid-receptor antagonists (CB1)
  • Orforglipron
  • Oral GLP1 peptides
  • Medications taken once monthly


**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.


This week’s show brought to you by FRIDAY’S HEALTH.


If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.



Instagram @drseanwharton

Clinical Trials



Instagram -

Tiktok -



Join my Weight Loss Coaching Program for women, Best Weight

Recover Strong for Binge Eating -

Ontario OHIP-covered Obesity Medicine